The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Vivimed Labs to explain why its financial results for the quarter ended 30-June-2024 were not submitted in the format prescribed under Schedule III of the Companies Act, 2013. The issue was flagged under Regulation 33 of SEBI's Listing Obligations and Disclosure Requirements. As of the announcement, the company's response to the exchange is still awaited. No penalty or further action has been mentioned at this stage.
This is a procedural compliance query rather than a serious regulatory action, so the immediate impact on shareholders is limited. However, a delayed or unsatisfactory response could lead to further action from the exchange, which may affect sentiment around the stock.